Novo Nordisk is named as an OpenAI collaborator, but the story reports no new project or result for it. A separate AI study did not show whether designed proteins could neutralize venom, so the article does not change Novo Nordisk's outlook.
The article names Novo Nordisk as an OpenAI collaborator, but gives no new project details or results for Novo Nordisk. OpenAI's purchase may add tools to its drug-development platform, yet the story does not say Novo Nordisk will use them. A separate AI study also did not show whether its designed proteins could neutralize venom. The report therefore does not change what we know about Novo Nordisk's business.
Moderna is named as an OpenAI collaborator, but the story reports no new project or result for it. A separate AI study did not show whether designed proteins could neutralize venom, so the article does not change Moderna's outlook.
Follow Novo Nordisk (NVO) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for NVO